A Fungal Infection, a 105-Degree Fever, and 16 Days in Hospital: What the New SmartPort Lawsuit Alleges — and Who Should Check Their Port

A Texas woman implanted with an AngioDynamics SmartPort in January 2026 for chemotherapy says the device gave her a Candida bloodstream infection, a fever above 105 degrees, suspected sepsis, and 16 days in hospital before surgeons removed the port in March. Her complaint, filed October 22, 2026, is the newest chapter in the port catheter litigation.

A port catheter is a small implanted device, a port under the skin connected to a thin tube into a vein, that lets doctors give chemotherapy and other infusions without a new needle stick each time. For readers who want video explainers of similar consumer and medical-device cases, the Problem Solved channel covers them in plain language. The Wofford case matters because it turns a familiar device failure, a fracturing catheter, into an infection story with a precise timeline.

Key Facts

  • Implanted January 2026, right side of the chest, for chemotherapy; hospitalised in March 2026 with a fever above 105 degrees Fahrenheit, chills, confusion, fatigue, and weakness.
  • Blood cultures identified Candida, a fungal infection of the bloodstream, traced to the SmartPort, which was surgically removed later in March during a 16-day hospital stay.
  • Complaint filed October 22, 2026, in the Southern District of California by Gretchen Wofford against AngioDynamics Inc. and Navilyst Medical Inc.
  • Federal AngioDynamics port catheter cases are consolidated before Judge Jinsook Ohta in the Southern District of California, covering SmartPort, Vortex Port, Xcela, and other devices.
  • For comparison, the Bard PowerPort docket held 4,140 pending federal cases as of October 1, 2026, with a $40 million second bellwether verdict on September 4, 2026.

What Happened to Gretchen Wofford

According to the complaint as reported on October 30, 2026, Wofford received her SmartPort in January 2026 so she could receive chemotherapy. In March she went to hospital for brachytherapy, a form of internal radiation treatment, and was found to have an acute fever above 105 degrees with chills, confusion, fatigue, and weakness. She was admitted on suspicion of sepsis, a life-threatening response to infection in which the body begins to injure its own tissues.

Blood cultures then identified Candida, a genus of fungi that can cause bloodstream infection, and further testing traced the infection to the SmartPort. The device was surgically removed later that month while she received broad-spectrum antibiotics, antimicrobial, and antifungal medicines. The complaint says she spent 16 days in hospital and suffered serious injuries and medical expenses. These are the complaint’s allegations; the companies have not, in the coverage reviewed, been reported to have answered this complaint yet, and no court has decided whether the device caused her infection.

The Design Allegation: Barium Sulfate and Fracturing Ports

The central design claim is strikingly specific. Port catheter lawsuits allege that manufacturers used too much barium sulfate, a substance added to catheter tubing so it shows up on imaging, in the polyurethane catheter. When too much is added, the allegation runs, the material degrades faster than expected, the catheter fractures after implantation, and broken pieces can migrate through the body, including to the heart and lungs, or perforate blood vessels.

A fractured port does two kinds of harm at once. The break itself can cause bleeding, blood clots, heart rhythm problems, and the danger of a fragment reaching the lungs. The break also creates a surface where infectious material can take root, which is how a device problem becomes a bloodstream infection. Wofford’s complaint quotes the adverse event reports she says the companies received for years: reports of SmartPorts fracturing after implantation, of fragments migrating through the body, and of ports perforating internal blood vessels, beginning soon after the device reached the market and years before her own implant.

The complaint pleads negligence, design defect, manufacturing defect, failure to warn, breach of warranty, fraudulent concealment, and violation of the Texas Deceptive Trade Practices Act. The failure-to-warn claim is the thread that ties the older reports to her January implant: if the companies knew of fracturing and infection reports for years, the argument goes, patients and their doctors should have been told in terms clear enough to change a decision.

Where the AngioDynamics Cases Stand

Federal AngioDynamics port catheter claims are consolidated in the Southern District of California before Judge Jinsook Ohta for coordinated discovery and pretrial proceedings, a procedure called multidistrict litigation, or MDL. An MDL is not a class action: each plaintiff keeps an individual case, but the cases share discovery and pretrial rulings before one judge so the same documents and experts are not fought over hundreds of times.

The Bard PowerPort docket shows what the AngioDynamics docket may look like in a year or two. A bellwether trial is an early test case, chosen to show both sides how a jury reacts to shared evidence; its verdict does not bind other cases, but it shapes settlement talks. Bard’s first bellwether, Cook, ended in May 2026 with a defence verdict on the warning claims and a hung jury on design defect. The second, Divelbliss, ended on September 4, 2026, with a $40 million verdict for a New Mexico woman whose catheter fractured and caused a pulmonary embolism, a blood clot in the lungs. The third, Lattanzio, an infection case brought by a Florida woman, began on October 13 and was scheduled through October 30. Two more Bard bellwethers follow: Hicks on December 1, 2026, and a fifth trial on February 2, 2027. Readers can follow that sequence in our report on Bard’s third PowerPort bellwether, now in trial and in the earlier summary of PowerPort verdicts and who can file.

One contrast matters for anyone comparing the two dockets. Bard’s infection theory has already been tested once, in Cook, with a mixed result; AngioDynamics’ infection theory is now being framed in complaints like Wofford’s, where the infection, not just the fracture, is the injury. Infection cases give defendants a wider set of alternative-causation arguments, because a hospitalised chemotherapy patient faces many possible sources of infection. That is why the blood culture evidence, the tracing of the infection to the device, and the removal record matter so much in Wofford’s account.

Who Benefits From This — and Who Does Not

People with an implanted AngioDynamics port benefit directly: this case gives them a concrete symptom list, fever above 105 degrees, chills, confusion, fatigue, and weakness, that should send them to urgent care rather than to watchful waiting, and a records checklist that protects any later claim. Families of chemotherapy patients benefit too, because they are often the first to notice confusion or a rising fever at home and the first to ask whether the port itself is the source.

People who already have a port catheter claim benefit in a different way. The Bard sequence, a defence verdict, then a $40 million fracture verdict, then an infection bellwether, shows that fracture evidence and infection evidence persuade juries differently, and that distinction should shape which documents a lawyer requests first. Our guide to PowerPort fracture and migration claims explains the device history that lawyers check before filing.

Who does not benefit? Anyone who never had an implanted port catheter gains nothing from this complaint, and neither does a patient whose infection was already traced to a different, proven source. People whose port was removed years ago without incident, and who have no symptoms, should not treat this complaint as a reason to seek removal: removing a working port carries its own risks and is a medical decision, not a legal one. Finally, this article helps no one who needs urgent care right now: a suspected bloodstream infection is an emergency, and the hospital comes before any lawyer.

What to Do If You Have a Port Catheter

First, know your device. Ask your treating team for the manufacturer and model, and keep the implant note with your medical records. Second, treat fever, chills, confusion, or pain, swelling, and redness around the port as reasons to seek care the same day and to mention the port immediately, because bloodstream infections move fast in patients receiving chemotherapy. Third, never try to remove, flush, or adjust the port yourself. Fourth, if an infection is diagnosed, keep the blood culture results, the removal note, and every hospital bill: those four items are the backbone of any later claim. Fifth, check the filing deadline in your state promptly with a product liability lawyer, since deadlines differ by state and by the date the injury was, or should have been, discovered.

Frequently Asked Questions

What does the new SmartPort lawsuit allege?

It alleges that a defective AngioDynamics SmartPort port catheter fractured or degraded inside the body, allowed infectious material to take hold, and caused a Candida bloodstream infection that required surgical removal of the device and 16 days in hospital. The complaint also alleges that the companies failed to warn patients and doctors adequately despite years of adverse event reports.

Who benefits from following this case?

People who have an implanted AngioDynamics port catheter, and families of chemotherapy patients who rely on one, benefit most: the case explains which symptoms should trigger urgent care, which records matter, and how the federal cases are organised. People already pursuing a port catheter claim also benefit, because the Bard bellwether results show how juries weigh fracture and infection evidence.

Who does not benefit from this case?

This case does not help people who never had an implanted port catheter, or whose infection has already been traced to a different, proven cause. It also does not decide any individual claim: a complaint is an allegation, not a finding, and each case still turns on its own medical records and device history.

How do I start if I think my port caused an infection?

First, seek medical care promptly for fever, chills, confusion, or redness and pain around the port, and tell the treating team you have an implanted port. Second, gather the implant record, the device model and serial number if available, hospital notes, and blood culture results. Third, speak promptly with a product liability lawyer about the filing deadline in your state, because deadlines vary and some run from the date the injury was discovered.

How are the AngioDynamics cases different from the Bard PowerPort cases?

They involve a different manufacturer and a different federal court: AngioDynamics cases are consolidated in the Southern District of California before Judge Jinsook Ohta, while Bard PowerPort cases sit in the District of Arizona before Judge David G. Campbell. Both groups allege fracturing ports and infection, but the Bard docket already has three bellwether trials behind it, while the AngioDynamics docket is still in coordinated pretrial proceedings.

Has there been a settlement for SmartPort claims?

The October 30, 2026 coverage of the new complaint does not describe a settlement of the AngioDynamics cases. The complaint seeks compensatory and punitive damages. Compensation varies widely by case, and most settlements are confidential, so no general per-claim figure can honestly be stated.

This article is general information about a pending lawsuit, not legal or medical advice. Allegations in a complaint are not findings of fact, and anyone with symptoms of a bloodstream infection should seek urgent medical care.

Watch on YouTube

Problem Solved on YouTube